Overview

Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function

Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether a dosing adjustment is needed in patients with renal impairment.
Phase:
Phase 4
Details
Lead Sponsor:
ViiV Healthcare
Collaborator:
Pfizer
Treatments:
Maraviroc
Ritonavir
Saquinavir